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Abstract 
We demonstrate that intestinal inflammation caused by the environmental contaminant 
benzo[a]pyrene increases the risk of developing type 2 diabetes. Our in vivo results indicate 
that a high-fat diet (HFD) induces a pre-diabetic state in mice compared with animals fed 
normal chow. HFD increased IL-1βmRNA concentration in the jejunum, colon, and liver, and 
TNFα was increased in the colon and strongly increased in the liver. HFD also increased the 
expression of other genes related to type 2 diabetes, such as the uncoupling protein UCP2, 
throughout the bowel and liver, but not in the colon. The treatment of HFD with  BaP 
enhanced the expression of IL-1β in the liver and TNFα throughout the bowel and in the liver. 
Adding BaP to the diet also caused a significant decrease in the expression of the incretin 
glucagon-like peptide 1, which plays an important role in insulin secretion. Our results  
suggest that intestinal inflammation may be involved in the onset of type 2 diabetes and that 
chronic exposure to environmental polycyclic aromatic hydrocarbons can increase the risk of 
type 2 diabetes by inducing pro-inflammatory cytokine production. 
 
Key words: Inflammation, high-fat diet, polycyclic aromatic hydrocarbon, benzo(a)pyrene, 
type 2 diabetes, GLP-1 
Introduction 
Polycyclic aromatic hydrocarbons (PAHs) such as benzo[a]pyrene (BaP) are major 
environmental contaminants. PAHs are generated primarily from incomplete combustion of 
organic materials and are found in charcoal-barbecued foods. Mainly through the Ah receptor 
(AhR) signaling pathway, PAHs regulate the expression of several genes including pro- 
inflammatory cytokines. Cells exposed to PAHs overexpressed IL-1β, IFNγ and IL-8 [1,2,3]. 
Similar results were obtained with other AhR ligands, such as dioxins, which trigger the 
induction of IL-1β and TNFα in hepatic inflammation. 
Several studies have shown that cigarette smoking increases the risk of type 2 diabetes (T2D) 
[4]. Smokers are more resistant than non-smokers to insulin-mediated glucose uptake and 
more hyperinsulinemic in response to an oral glucose load [5]. In the same way, persons 
exposed to dioxins or polychlorobiphenyls (PCBs) are at higher risk for metabolic diseases 
such as T2D [6]. Dioxins and PCBs are also well-known AhR ligands [7], and are present at 
various levels in food. 
 
Most people with T2D are overweight, have low physical activity, and have relatives with 
diabetes. Poor dietary habits are definitely considered as a major risk factor responsible for  
the increased occurrence of diabetes today [8]. Several studies have shown that inflammation 
is closely correlated with the development of T2D [9], as attested by the high plasma 
concentration of C-reactive protein CRP and pro-inflammatory cytokines IL-6 and TNFα  
[10]. Hence both genetic and environmental factors, such as diet, physical inactivity, smoking 
and oxidative stress are responsible for the initiation and progression of chronic inflammation 
[11]. The origin of the inflammation is unknown, but a recent original hypothesis suggested 
that high-fat diet-induced obesity was associated with gut inflammation and with a 
modification of the gut microflora [12,13]. 
We hypothesized that BaP could potentiate the development of HFD-induced T2D through  
the modulation of the expression of genes implicated in inflammatory response and oxidative 
balance in the bowel. The aim of the present study was therefore to investigate the effects of 
BaP in the context of high-fat diet-induced diabetes on gut inflammation and its influence on 
the development of T2D. 
Materials and methods 
 
Animal preparation and treatment 
 
Four- to five-week-old male C57B6/6J mice (IFFACREDO, L’Arbresle, France) were 
maintained on three types of diet: a normal chow diet (NC, energy content: 12% fat, 28% 
protein, and 60% carbohydrate), a high-fat diet (HFD) (energy content: 72% fat comprising 
corn oil and lard, 28% protein, and < 1% carbohydrate), as described [14], and a high-fat diet 
supplemented with benzo[a]pyrene (BaP, 2.5 mg/kg bw) for 5 weeks. Ten mice per cage were 
kept under an 8 am-to-8 pm dark cycle. Blood was collected at 2 pm in the fed state. For 
fasting experiments and blood sampling, food was removed at 8 pm, and the mice were kept  
in a new clean cage for 6 h. During the study, food intake, weight gain and glycemia were 
measured as previously described [15,16]. 
Intraperitoneal glucose tolerance test 
 
An intraperitoneal glucose tolerance test (IPGTT),) was given to 6 h-fasted mice after one 
month (5 weeks) of diet treatment (intraperitoneal injection of 1 g/kg body weight of glucose). 
Blood glucose levels were monitored from the tip of the tail vein with a glucose meter (Roche 
Diagnostic, Rotkreuze, Switzerland) from a 3.5 µl sample of tail blood at 30, 0, 30, 60, and 
90 min after glucose injection [17]. Areas under the curve (AUC) (30-90) were calculated 
for each group HFD, HFD+BaP and the NC group. 
 
RNA extraction and real time PCR 
 
At the end of treatment the animals were sacrificed, and the four parts of the bowel and the 
liver were excised. Total RNA was isolated from the tissues using Trizol reagent (Invitrogen, 
France), RNA was quantified by NanoDrop (NanoDrop technologies Inc.,  France).  Total 
RNA (1 μg) was reverse-transcribed using Moloney murine leukemia virus reverse- 
transcriptase (Invitrogen, Cergy-Pontoise, France) and random primers at 42 °C for 1 h. The 
expression of target genes was determined using the Lightcycler 480 System (Roche, France). 
To avoiding pipetting errors we used a Biomek3000 pipetting robot equipped with a 96- 
channel head (Bekman and Coulter). PCR was performed with 0.5 μM of each primer and 
with the LightCycler and Mastermix Plus for SYBR™GreenI No ROX, in a total volume of 
10 μl. Cycling conditions were as follows: 10 min denaturing at 95 °C, followed by 40 cycles 
of 30 s denaturing at 95 °C, 30 s primer annealing at 60 °C and 30 s fragment elongation at   
72 °C. The melting curve was analyzed with the LightCycler® 480 gene scanning software. 
Mouse IL-1β, TNFα, IL-10, TGFβ, GLP-1, UCP2, and UPC3 expressions were normalized to 
β2-actin expression and data quantified by the method of 2־
∆∆Ct 
[18]. The primers used are 
listed in Table 1. 
 
 
Statistical analysis 
 
Statistical analysis was performed using the Mann-Whitney test by means of GraphPad 
Software. Values were considered statistically different when P < 0. 05. Results are presented 
as means ± SD. 
Results 
We analyzed the effect of HFD compared with NC on the inflammatory state linked to type 2 
diabetes. We studied, on the same genes, the effect of a supplementation of HFD with BaP 
(HFD+BaP) compared with the HFD alone. The tissues studied were the segmented bowel 
(duodenum, jejunum, ileum and colon) and the liver. 
 
Effect of HFD versus NC diet on the intestinal and hepatic expression of some target 
genes (Fig. 1) 
We observed a significant induction by HFD of pro-inflammatory IL-1β gene expression in 
the jejunum (2.8-fold) and colon (1.8-fold). 
We also analyzed the gene expression of another pro-inflammatory cytokine, TNFα. TNF 
was only significantly induced in the colon (1.7-fold). In the liver, the gene expression of both 
cytokines IL-1β and TNFα were strongly induced by the HFD (2.8-fold and 13.9-fold 
respectively). 
To check the anti-inflammatory response, the expression of TGF and IL-10 genes was 
analyzed. The results indicate that in the bowel, TGFβ expression was significantly induced in 
the jejunum (1.7-fold) and colon (1.5-fold) similarly to what was observed for IL-1. No 
significant variation in TGF expression was observed in the duodenum or ileum. The 
expression of IL-10, which plays an important role in the inflammatory homeostasis of the 
bowel, was also analyzed. This anti-inflammatory cytokine was significantly down-regulated 
in the ileum (0.25-fold) and colon (0.5-fold). IL-10 gene expression was not detected in the 
upper bowel (duodenum and jejunum). 
In the liver, we did not observe any significant variation in either TGFβ or IL-10 gene 
expression. 
We also analyzed the expression of uncoupling proteins 2 and 3 (UCP-2 and UCP-3) involved 
in the oxidative status, which play an important role in metabolic syndrome [19]. The results 
presented indicated that UCP2 expression was significantly increased in the upper bowel, in 
particular in the duodenum, jejunum and ileum (3.7-, 2.5- and 1.6-fold increase respectively). 
In contrast, a significant decrease of UCP2 expression was observed in the colon (0.8-fold). 
We also analyzed UCP3 gene expression. This gene was induced in the jejunum (2.6-fold)  
and ileum (1.8-fold). 
In the liver, gene expression of UCP2 was significantly induced (1.9-fold). UCP3 was not 
detected in this tissue. 
 
Effect of BaP added to HFD versus HFD on the intestinal and hepatic expression of some 
target genes (Fig 2) 
The presence of BaP in HFD did not affect HFD-induced IL-1β gene expression in the bowel 
or liver. In contrast, TNFα was significantly induced (around 2-fold) in all tested tissues  
except for the ileum. 
Concerning genes associated with the anti-inflammatory response, the addition of BaP 
significantly decreased the expression of TGFβ in the ileum and slightly in the rest of the 
bowel. No significant variation was observed in the liver. In contrast, IL-10 expression was 
significantly increased in the colon (1.4-fold) and liver (2-fold). 
UCP2 expression was significantly decreased in response to addition of BaP only in the upper 
bowel: duodenum (0.4-fold) and jejunum (0.7-fold). By contrast, this gene was significantly 
induced in the liver (2.2-fold). 
No significant variation was observed in UCP3 expression in the jejunum, ileum, colon or 
liver. 
 
To evaluate the physiological effects of the diet, we analyzed the glucagon-like peptide 1 
incretin (GLP-1), which is known to play an essential role in insulin secretion, and the 
biochemical data characteristics of type 2 diabetes (food intake, weight, and IPGTT). 
The results presented in Figure 1 indicate that compared with a normal diet, GLP-1 was not 
significantly modulated by HFD in the ileum or colon. Compared with HFD alone, the 
presence of BaP in HFD significantly decreased GLP-1 gene expression in the ileum (0.4- 
fold) and colon (0.4-fold). No expression of this gene was found in the liver, jejunum or 
duodenum. 
 
Effect of HFD or BaP added to HFD on food intake 
As shown in Figure 3A, no significant variation of food intake was observed during the 
treatment when the HFD mice were compared with the NC diet mice. The same results were 
observed when the HFD+BaP mice were compared with HFD mice. 
Effect of HFD or BaP added to HFD on body weight gain 
As shown in Figure 3B, no significant body weight gain was observed during the treatment 
when the HFD mice were compared with the NC diet mice. The same results were observed 
when we compared the HFD+BaP group with the HFD group. 
Effect of HFD or BaP added to HFD on glucose tolerance 
 
As shown in Figure 3C, HFD mice exhibited significant glucose intolerance when compared 
with the normal chow diet mice, as evidenced by the significant higher AUC calculated from 
glucose profiles (Fig.3D). By contrast, no significant glucose intolerance was observed when 
the HFD+BaP mice were compared with the HFD mice (Fig. 3C and D). 
 
Discussion 
 
T2D is a major public health concern. It is closely linked to obesity, and is associated with an 
increased risk of cardiovascular events. Although genetic predispositions to T2D have been 
described, environmental factors play a major role in the etiology of this metabolic disease. 
The influences of a hypercaloric diet associated with a decrease in physical activity have been 
widely described as the main factors in decreased insulin sensitivity. However, 
epidemiological studies have demonstrated that other environmental factors are also involved. 
It has now been clearly demonstrated that environmental exposure to dioxins and 
polychlorobiphenyls (PCB) is associated with an increased the risk of T2D and metabolic 
syndrome [20,21,22,23]. Similar effects have been observed in tobacco smokers [24,25,26]. 
Dioxins, PCBs and PAHs are well-known AhR ligands [27,28]. Although extensive data 
demonstrate that these chemicals enhance susceptibility to chemical carcinogenesis by 
inducing CYP1 expression, much recent work shows that AhR activation leads to an  
induction of pro-inflammatory cytokines such as IL-1β and TNFα [29,30]. T2D and decreased 
insulin sensitivity have been associated with an increase in circulating TNFα levels. It is 
known that the increase in TNFα is a consequence of the inflammation of the visceral adipose 
tissue. 
We investigated the involvement of the bowel in the nutrient-induced inflammatory response, 
given that this tissue has primary contact with food. We compared the response of the bowel 
with that of the liver. 
As diabetes is known to be associated with some disturbances of inflammatory status, we 
analyzed the inflammatory gene expression in response to HFD, in both the bowel and the 
liver. The induction of inflammation following HFD is already well-documented in the liver 
and our results are consistent with previous published data [12, 34, 35]. In the bowel, 
amplitude of the inflammatory response was specific to the intestine segment considered. 
Alltogether, the study of intestinal IL-1β and TNFα expression shows that the response was 
similar to what was observed in the liver. We note that except in the colon, we found in all 
parts of the bowel an association between pro-inflammatory gene expression and UCP 
induction. As previously reported by others, no TGFβ or IL10-induced anti-inflammatory 
response was observed in the liver. However, in the jejunum and colon, but not in the 
duodenum or ileum, TGFβ seems to play an important role after HFD by counteracting the 
inflammatory process. When BaP was added to HFD, we observed an amplification of the 
inflammatory response in both the bowel and the liver. Compared with IL-1, TNF appears 
as the main inflammatory cytokine enhanced in response to the presence of BaP in HFD. The 
HFD-induced anti-inflammatory response, represented by TGFβ expression, was reduced by 
BaP treatment in all parts of the intestine. Thus in the presence of BaP, the HFD-induced 
inflammation status was amplified through both an enhancement of pro-inflammatory 
cytokines and a down-regulation of anti-inflammatory cytokines. This process, induced first  
in the intestine, may contribute to further deterioration of the metabolism. By contrast, in both 
the colon and the liver, HDF-induced IL-10 expression was further enhanced by addition of 
BaP. In this case, the colon and liver displayed similar patterns of anti-inflammatory response. 
The up-regulation of IL10 we observed in the liver and colon may be the main factor that 
reduces the inflammatory process in these tissues. These data indicate that the bowel, the first 
target of food constituents, may play a role in the modulation of the inflammatory status. 
We analyzed the expression of uncoupled proteins (UCP2 and UCP3), which are modulators 
of inflammatory response mediated by redox balance and linked to diabetes emergence. In 
general, in various tissues already analyzed, expression of the UCP gene family was increased 
by HFD. UCP2 was induced by the HFD in the main parts of the bowel comprising the 
duodenum, jejunum and ileum. This response is similar to that observed in the liver as  
reported in this work and elsewhere [31,32]. By contrast, the colon presents a different pattern 
of UCP2 expression, with a decrease in its expression. UCP3 was detected in the jejunum, 
ileum and colon with only a significant induction in the jejunum. These data are original and, 
to our knowledge, no data were available concerning the expression of UCP2/3 in the  
different parts of the bowel compared with the liver. Thus as previously reported by others in 
the liver [31,32,33], HFD modifies UCP2/3 expression, and this response appears to be 
differently regulated according to the part of intestine tested. When added to HFD, BaP 
partially counteracted the effect of HFD on UCP2 expression, which was found to be 
decreased in the upper bowel, including the duodenum and jejunum. However, this response 
was opposite to that of the liver, where BaP enhanced the HFD-induced UCP2 expression. 
Thus unexpectedly, the disturbance of metabolism induced by HFD seems  to be ‘normalized’ 
in the bowel by BaP addition, but amplified in the liver. BaP induced no variation in UCP3 
expression, showing that the effects of BaP are gene-specific. 
We further analyzed the effect of HFD alone or BaP+HFD on GLP-1 expression, since it 
normalizes blood glucose level by increasing circulating insulin and decreasing glucagon 
secretion. When BaP was added to HFD, we observed a significant decrease in GLP-1 
expression in the bowel, particularly in the terminal parts ileum and colon. AhR ligands, 
acting as inflammatory compounds and decreasing GLP-1 expression may be involved in the 
onset of diabetes. Biochemical data (IPGTT) show that HFD treatment reduced insulin 
sensitivity, but BaP supplementation did not modify this effect. 
Overall, our findings show that the bowel may play a role in this process. 
 
 
Conclusion 
Our results show that PAHs, by activating AhR, are involved in the potentiation of the 
inflammatory process induced by HFD. The inflammation occurs in the bowel, one of the first 
organs exposed to dietary constituents. This inflammation may be involved in the 
inflammatory stimulation of other organs such as the liver. In the bowel, the colon seems to 
play a specific role in this effect. 
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Figure legends 
 
 
Fig.1. Effect of high-fat diet (HFD) versus normal chow diet mice (NC) on relative gene 
expression levels in the bowel (duodenum, jejunum, ileum and colon) and liver of five-week- 
old male C57B6/6J mice. *: p < 0.05, **: p < 0.01. ND: not done, UD: undetected. 
Fig.2. Effect of benzo[a]pyrene added to high-fat diet (HFD+BaP) versus high-fat diet mice 
(NC) on relative gene expression levels in the bowel (duodenum, jejunum, ileum and colon) 
and liver of five-week-old male C57B6/6J mice. *: p < 0.05, **: p < 0.01. ND: not done, UD: 
undetected. 
 
 
Fig.3. Effect of HFD or BaP added to HFD on the biochemical data characteristics of type 2 
diabetes of five-week-old male C57B6/6J mice. A: Food intake (g) for 5 weeks of treatment. 
B: Body weight (g). C: glycemia after 5 weeks of dietary treatment were calculated at 30, 0, 
30, 60 and 90 min after glucose injection. D: areas under the curves (AUCs) of glucose 
tolerance tests calculated from Fig 3, C. Results are mean ± SD. **: p < 0.01, ***: p < 0.001. 
 
Table 1 
 
Genes Forward sequence (5'-3') Reverse sequence (5'-3') 
β2-actin 5'-AAGGCCAACCGTGAAAAGAT-3' 5'-TGGTACGACCAGAGGCATAC-3' 
TNFα 5′-GGGACAGTGACCTGGACTGT-3′ 5'-TTCGGAAAGCCCATTTGAGT-3′ 
IL-1β 5'-TCGCTCAGGGTCACAAGAAA-3' 5'-CATCAGAGGCAAGGAGGAAAA-3' 
TGF-β 5'-TGGAGCAACATGTGGAACTG-3' 5'-GTCAGCAGCCGGTTACCA-3' 
IL-10 5'-CACAAAGCAGCCTTGCAGAA-3' 5'-AGAGCAGGCAGGATAGCAGTG-3' 
UCP-2 5′-CTCCCAATGTTGCCCGTAAT-3′ 5′-GGCTTTCAGGAGAGTATCTTTGA-3′ 
UCP-3 5′-GCTGGAGTCTCACCTGTTTACT-3′ 5'-ACAGAAGCCAGCTCCAAAGG-3' 
GLP-1 5′-ACATGCTGAAGGGACCTTTAC-3′ 5′-GGCTTTCACCAGCCAC-3′ 
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